Bio-Techne Third Quarter 2025 Earnings: EPS Misses Expectations

Simply Wall St · 4d ago

Bio-Techne (NASDAQ:TECH) Third Quarter 2025 Results

Key Financial Results

  • Revenue: US$316.2m (up 4.2% from 3Q 2024).
  • Net income: US$22.6m (down 54% from 3Q 2024).
  • Profit margin: 7.1% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: US$0.14 (down from US$0.31 in 3Q 2024).
earnings-and-revenue-history
NasdaqGS:TECH Earnings and Revenue History May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bio-Techne EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 57%.

Looking ahead, revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 1.8% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Bio-Techne that you should be aware of before investing here.